Interview with John Norman, Country Manager, Nycomed South Africa
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
Address: South Wing, The Place, 1 Sandton Drive, Sandton, 2196
P O Box 784746, Sandton City, Sandton, 2146 ,South Africa
Tel: (+27-11) 783 0104
Web: http://www.drreddys.com/southafrica/
Dr. Reddy’s – South Africa operation is a wholly-owned subsidiary and one of the leading generics players in the country. With a dedicated field force it focuses on key therapeutic areas like Central Nervous System (CNS) and Primary Care.
The business performance in South Africa has been phenomenal in the last few years. The overall revenue as per FY10 has been at $9.4 million enlisting a 56% growth.
Its advantageous position is ensured through the presence of key contributors in its business model. The Research & Development capability helps the company ensure enhanced FTL Opportunities through non-infringing pdts and supports differentiation with products and competitors. Alongside, the in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. The company’s Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket. All the more its committed filed force has also been promising in recent years while reaching to all segments of the market.
In the South Africa Generic market Dr. Reddy’s is ranked 18th in terms of Value and 20th in terms of volume (Source: IMS-SA IGMS, MAT, Nov. 2010).
Top-five products including Omez, Cifloc, Citraz, Amlate and DRL-Moxifloxacin contribute to over 50% of revenue.
Products cathegories:
Active Pharma Ingredients (API)
Custom Pharma Services (CPS)
Global Generics
New Chemical Entities (NCEs)
Differentiated Formulations
Biosimilars
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Mr. Daniel, after working with Pfizer Australia, working in Hong Kong as Regional Marketing Director for the Asian operation and in Japan, you have been the first South African appointed…
South Africa has recently achieved the 1st Millennium Development Goal (MDG) – reducing the proportion of the population living on less than 1 USD a day by half – but…
Our international readers know about South Africa’s socio-economic relative achievements, considering the country joined the BRICS grouping last year and achieved the first Millennium Development Goal (MDG) that same year.…
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
See our Cookie Privacy Policy Here
